Oral GLP-1 Formulations and Future Projections Several companies are developing oral GLP-1 formulations, including Novo Nordisk, Pfizer, and smaller firms, positioning them as potential acquisition targets
The formulation is stabilized using excipients such as citric acid, mannitol, and polysorbate 80, while an automated needle mechanism facilitates self-injection by extending and retracting the needle, thereby improving patient adherence and ease of use
Huang Y, Wang X, Li W, Yue F, Wang M, Zhou F
Signals The Brain To Stop Eating (Satiety): GLP-1 crosses the blood-brain barrier and interacts with appetite-regulating receptors in the hypothalamus
The choice between medications should consider individual tolerance, weight loss efficacy, and other factors
These growing cases and raised efficacy with enhanced glycemic control and weight loss make them a preferred treatment option for many patients